Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
NCT06748495
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
600
Enrollment
OTHER
Sponsor class
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sponsor
Hunan Cancer Hospital